Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Page 1
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Lancet Neurol. 2017 Jul;16(7):505-512. doi: 10.1016/S1474-4422(17)30115-1. Epub 2017 May 15.
Lancet Neurol. 2017.
PMID: 28522181
Clinical Trial.
Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP.
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP.
Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):55-63. doi: 10.1080/21678421.2017.1364269.
Amyotroph Lateral Scler Frontotemporal Degener. 2017.
PMID: 28872920
Clinical Trial.
Item in Clipboard
Edaravone for treatment of early-stage ALS - Authors' reply.
Akimoto M, Nakamura K; Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group.
Akimoto M, et al.
Lancet Neurol. 2017 Oct;16(10):772. doi: 10.1016/S1474-4422(17)30290-9. Epub 2017 Sep 12.
Lancet Neurol. 2017.
PMID: 28920878
No abstract available.
Item in Clipboard
Cite
Cite